GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CKD Bio Corp (XKRX:063160) » Definitions » Debt-to-Equity

CKD Bio (XKRX:063160) Debt-to-Equity : 1.19 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is CKD Bio Debt-to-Equity?

CKD Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩76,503 Mil. CKD Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩70,423 Mil. CKD Bio's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩123,024 Mil. CKD Bio's debt to equity for the quarter that ended in Dec. 2023 was 1.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CKD Bio's Debt-to-Equity or its related term are showing as below:

XKRX:063160' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03   Med: 0.13   Max: 1.19
Current: 1.19

During the past 13 years, the highest Debt-to-Equity Ratio of CKD Bio was 1.19. The lowest was 0.03. And the median was 0.13.

XKRX:063160's Debt-to-Equity is ranked worse than
88.93% of 849 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs XKRX:063160: 1.19

CKD Bio Debt-to-Equity Historical Data

The historical data trend for CKD Bio's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CKD Bio Debt-to-Equity Chart

CKD Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.47 0.68 0.94 1.19

CKD Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 0.98 1.03 1.21 1.19

Competitive Comparison of CKD Bio's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, CKD Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CKD Bio's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CKD Bio's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CKD Bio's Debt-to-Equity falls into.



CKD Bio Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CKD Bio's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

CKD Bio's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CKD Bio  (XKRX:063160) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CKD Bio Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CKD Bio's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CKD Bio (XKRX:063160) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjeongno 3-ga, Seodaemun-gu, Seoul, KOR, 120-756
CKD Bio Corp is engaged in manufacturing and distribution of pharmaceutical materials and medicines. Its products portfolio include antibiotic, lactamase inhibitors, antituberculosis, antidiabetics, immunosuppressants, antihyperlipidemics, intermediates, and probiotics.

CKD Bio (XKRX:063160) Headlines

No Headlines